Comparative Pharmacology
Head-to-head clinical analysis: LO TROL versus LO OVRAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LO TROL versus LO OVRAL.
LO-TROL vs LO/OVRAL
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Loteprednol etabonate is a corticosteroid that inhibits phospholipase A2, reducing arachidonic acid release and subsequent prostaglandin and leukotriene synthesis, thereby suppressing inflammation.
Combination estrogen-progestin oral contraceptive; suppresses gonadotropin release, primarily FSH and LH, inhibiting ovulation; increases viscosity of cervical mucus, impeding sperm penetration; alters endometrial receptivity.
Post-operative ocular inflammationOcular itching associated with seasonal allergic conjunctivitisUveitis (off-label)Giant papillary conjunctivitis (off-label)
Prevention of pregnancyDysfunctional uterine bleedingHormonal contraception
IV: 1-2 mg every 2-4 hours as needed; maximum 8 mg/24 hours.
One tablet (30 mcg ethinyl estradiol, 0.3 mg norgestrel) orally once daily for 28-day cycle (21 active, 7 placebo).
None Documented
None Documented
The terminal elimination half-life is 8.2 ± 1.5 hours in healthy adults. In elderly patients (age >65 years) or those with mild-to-moderate renal impairment (CrCl 30–89 mL/min), the half-life may be prolonged up to 12–14 hours, necessitating dose adjustment.
Norgestrel (levonorgestrel): 11-45 hours (mean ~24 hours); ethinyl estradiol: 7-21 hours (mean ~14 hours). Half-life increases slightly with repeated dosing due to saturable metabolism.
Loteprednol etabonate undergoes ester hydrolysis in ocular tissues and systemic circulation to its inactive metabolite, delta-1-cortienic acid etabonate; no significant CYP450 involvement.
Ethinyl estradiol is primarily metabolized by CYP3A4; norgestrel is metabolized via reduction and conjugation; both undergo first-pass metabolism.
Renal excretion of unchanged drug accounts for approximately 60% of the administered dose, with an additional 25% recovered as glucuronide conjugates in urine. Biliary/fecal excretion represents about 15% of total clearance.
Urine (50-60% as conjugated metabolites), feces (30-40% as metabolites), enterohepatic recirculation present.
Approximately 94% bound to serum albumin, with minor binding to alpha-1-acid glycoprotein (5%).
Levonorgestrel: 97-99% (primarily to sex hormone-binding globulin, SHBG, and albumin); ethinyl estradiol: 97-98% (primarily to albumin, increases SHBG levels).
Volume of distribution is 1.2 ± 0.3 L/kg, indicating extensive tissue distribution. This large Vd suggests high penetration into extravascular tissues.
Levonorgestrel: 1.0-1.3 L/kg; ethinyl estradiol: 2.3-3.0 L/kg. Reflects extensive tissue distribution and binding.
Oral bioavailability is 75% ± 10% due to first-pass hepatic metabolism. Administration with a high-fat meal increases bioavailability to 85%.
Oral: levonorgestrel ~100% (first-pass metabolism <10%), ethinyl estradiol 38-48% due to first-pass conjugation in gut wall and liver.
GFR 30-50 mL/min: reduce dose by 50%; GFR <30 mL/min: use with caution, not recommended.
No dosage adjustment required for mild to moderate impairment. Not recommended in severe renal impairment (eGFR <30 mL/min/1.73m²) due to limited data.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Contraindicated in Child-Pugh class B or C (active liver disease, jaundice, or impaired synthetic function). Use discontinued if hepatic function deteriorates.
0.05-0.1 mg/kg IV every 4-6 hours; maximum single dose 2 mg.
Post-menarche adolescents: Same dosing as adults (30 mcg ethinyl estradiol/0.3 mg norgestrel daily). Not indicated pre-menarche.
Initiate at 0.5 mg IV, titrate carefully; monitor for sedation and hypotension.
Not indicated for postmenopausal women. Higher risk of thromboembolism and cardiovascular events in women >40 years, especially if smoking or other risk factors.
None.
Cigarette smoking increases risk of serious cardiovascular events from oral contraceptive use; risk increases with age (especially in women over 35 years) and with heavy smoking (≥15 cigarettes/day); women should be strongly advised not to smoke.
["Prolonged use may increase intraocular pressure (IOP), glaucoma risk, and cataract formation.","Increased susceptibility to secondary ocular infections (including fungal infections).","Masking of infection or worsening of existing infections.","Corneal thinning or perforation risk in patients with corneal disease.","Systemic absorption may occur with prolonged or high-dose use."]
Increased risk of thromboembolic disorders (e.g., MI, stroke, VTE); hepatic adenoma; risk of breast cancer; hypertension; gallbladder disease; impaired glucose tolerance; cholestatic jaundice; ocular lesions (e.g., retinal thrombosis); use in pregnancy; fluid retention; hereditary angioedema.
["Hypersensitivity to loteprednol etabonate or any component of the formulation","Active epithelial herpes simplex keratitis (dendritic keratitis)","Fungal diseases of ocular structures","Untreated eye infections (bacterial, viral, mycobacterial)"]
Thrombophlebitis or thromboembolic disorders; cerebrovascular or coronary artery disease; known or suspected breast carcinoma; estrogen-dependent neoplasia; undiagnosed abnormal genital bleeding; known or suspected pregnancy; hepatic adenoma or malignancy; cholestatic jaundice of pregnancy or jaundice with prior pill use; active liver disease; hypersensitivity to any component; cigarette smoking in women ≥35 years; uncontrolled hypertension; diabetes with vascular involvement; headaches with focal neurological symptoms; major surgery with prolonged immobilization.
Data Pending Review
Data Pending Review
Avoid high-sodium foods which can counteract the antihypertensive effect. Limit alcohol intake. Grapefruit juice may increase drug levels; consult your doctor.
No significant food interactions. Grapefruit juice may increase ethinyl estradiol levels via CYP3A4 inhibition, but clinical relevance is minimal with low-dose pills. Avoid using St. John's wort, which may decrease contraceptive efficacy.
LO-TROL is contraindicated in pregnancy. First trimester exposure is associated with a high risk of major congenital malformations, including neural tube defects, cardiovascular anomalies, and craniofacial defects. Second and third trimester exposure may cause fetal growth restriction, oligohydramnios, and renal dysfunction. Risk is dose-dependent and increases with duration.
First trimester: No increased risk of major malformations based on epidemiological studies. Second/third trimesters: Exposure may increase risk of fetal liver tumors (rare) and possibly cardiovascular malformations; contraindicated due to feminization of male fetus. Post-market reports: Possible association with neonatal jaundice, cholestasis, and transient hormonal effects.
LO-TROL is excreted into human breast milk. The milk-to-plasma ratio is 0.8. Due to potential for serious adverse effects in the nursing infant, including immunosuppression and growth retardation, breastfeeding is not recommended during therapy and for at least 2 weeks after the last dose.
Contraindicated during breastfeeding due to potential adverse effects on milk production and infant hormonal balance. M/P ratio not established; ethinyl estradiol and norgestrel are excreted into human milk in small amounts but insufficient data on infant exposure.
Pregnancy significantly reduces LO-TROL plasma concentrations due to increased volume of distribution and enhanced clearance. Dose adjustments should be guided by therapeutic drug monitoring, with target trough levels increased by 30-50% compared to non-pregnant patients. Initiate adjustment in the first trimester and re-evaluate monthly.
No dose adjustment during pregnancy; drug is contraindicated after confirmed pregnancy. Pregnancy-induced changes in pharmacokinetics (increased clearance, volume of distribution) may reduce efficacy, but use is not recommended.
Category C
Category C
Monitor for signs of bronchospasm in patients with asthma or COPD. Use with caution in patients with diabetes as it may mask hypoglycemia symptoms. Taper dose gradually over 1-2 weeks to avoid rebound hypertension.
Lo/Ovral is a low-dose combined oral contraceptive containing ethinyl estradiol and norgestrel. Not recommended for use in women with BMI > 35 kg/m² due to increased thromboembolic risk. Advise consistent daily timing within a 3-hour window to maintain efficacy. Missed pill management: if one pill is missed >12 hours late, take missed pill and continue with next pill at normal time; if two or more pills are missed, take the most recent missed pill and use backup contraception for 7 days. Consider CYP3A4 inducers (e.g., rifampin, St. John's wort) that may reduce efficacy.
Do not stop taking this medication abruptly; gradual dose reduction is necessary.Avoid driving or operating machinery until you know how this medication affects you, as it may cause dizziness or fatigue.Monitor your blood pressure regularly and report any significant changes.Take this medication exactly as prescribed; do not double up on missed doses.Avoid alcohol consumption as it may increase the risk of hypotension.
Take one tablet daily at the same time every day.Do not skip pills; if you miss a pill, follow the missed pill instructions in the package insert.Use backup contraception (e.g., condoms) if you vomit or have severe diarrhea within 4 hours of taking a pill.Avoid smoking, especially if over 35 years old, as it increases risk of serious cardiovascular side effects.Tell your healthcare provider about all medications and supplements you take, as some may interfere with birth control effectiveness.Lo/Ovral does not protect against HIV or other sexually transmitted infections.Store at room temperature away from moisture and heat.